VivoSeq
Oncology

Glioblastoma

433

Pipeline Programs↗

202

Active Trials↗

142

Companies Involved↗

Glioblastoma is a highly competitive landscape with 433 programs across 142 companies. The most active players are Immatics Biotechnologies GmbH, Alaunos Therapeutics, Laminar Pharmaceuticals. 1 therapy is approved with 41 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

94/100

Pipeline Velocity

71/100

Mech. Concentration

4/100

Completion Rate

65/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

I

Immatics Biotechnologies GmbH

3 programs

Phase 1A

Alaunos Therapeutics

2 programs

Phase 1L

Laminar Pharmaceuticals

2 programs

Phase 1Merck & Co. logo

Merck & Co.

2 programs

Phase 1Arcus Biosciences logo

Arcus Biosciences

2 programs

Phase 1K

Katmai Pharmaceuticals Inc.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical16

Dexamethasone

Aspen Global Incorporated

Tislelizumab

BeiGene

Valganciclovir

Engelhard Arzneimittel GmbH & Co.KG

Apatinib

LaNova Medicines Zhejiang Co., Ltd.

Vorinostat

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 1157

Ubidecarenone Injectable Nanosuspension

Seema Nagpal

Pembrolizumab

Merck & Co.

Nivolumab

Bristol-Myers Squibb

Ivonescimab

Summit Therapeutics

Ezabenlimab

Boehringer Ingelheim

Phase 2218

Fluzoparib

Risen (Suzhou) Pharma Tech Co., Ltd.

Atezolizumab

Roche

Osimertinib

AstraZeneca

Olaparib

AstraZeneca

Vortioxetine

Takeda

Phase 341

Temozolomide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Losartan

Organon and Co

Lomustine

Azurity Pharmaceuticals

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Niraparib

Glaxo Dba Glaxosmithkline

Approved1

Tovorafenib

Day One Biopharmaceuticals

Analysis

Modality Breakdown

83%

Small molecule

373 of 451 classified programs — the dominant modality here.

17%ALL OTHERSMonoclonal antibody337%Vaccine194%Cell therapy143%Protein / enzyme82%Antibody–drug conjugate1<1%Peptide1<1%Other2<1%

Small molecule leads; the ring shows all 451 classified programs, each share of the total. Modality classified for 99% of 515 pipeline programs.

Analysis

Trial Status

609

clinical trials

Completed225 · 37%
Recruiting99 · 16%
Terminated79 · 13%
Active, not recruiting72 · 12%
Unknown status59 · 10%
Withdrawn34 · 6%
Other41 · 7%

Clinical Trials

Trial Activity

609 trials

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma
Recruiting·UUniversitair Ziekenhuis Brussel·Phase 1·NCT06097975·18 enrolled
Clinical Study of Oncolytic Virus in Glioblastoma
Recruiting·MMianyang Central Hospital·Phase 1/2·NCT07145047·20 enrolled
A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Recruiting·DDebiopharm International SA·Phase 1/2·NCT05765812·116 enrolled
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma
Recruiting·NNovoCure GmbH·Phase 3·NCT06556563·741 enrolled
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Recruiting·—·Phase 2·NCT06069726·80 enrolled
B7H3/IL13Ra2 Bispecific Armored Chimeric Antigen Receptor T-Cell Therapy Study for Recurrent/Refractory Glioblastoma
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT07193628·14 enrolled
Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Recruiting·BBaptist Health South Florida·Phase 2·NCT06991101·190 enrolled
Study of Metabolic, Transcriptomic and Proteomic Characteristics in Relapsed Glioblastoma
Recruiting·UUniversity Hospital, Bordeaux·N/A·NCT06430424·40 enrolled
Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT06934889·60 enrolled
Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients
Recruiting·JJonsson Comprehensive Cancer Center·Phase 3·NCT07461948·15 enrolled
Methimazole in Patients With Progressive Glioblastoma
Recruiting·—·Phase 2·NCT05607407·19 enrolled
The Assessment of Immune Response in Newly Diagnosed Glioblastoma Patients Treated With Pembrolizumab
Recruiting·MMedical University of Silesia·Phase 4·NCT05235737·36 enrolled
CUE-102 in Recurrent Glioblastoma
Recruiting·—·Phase 1·NCT06917885·18 enrolled
Sacituzumab Govitecan in Recurrent Glioblastoma
Recruiting·TThe University of Texas Health Science Center at San Antonio·Phase 2·NCT04559230·32 enrolled
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
Recruiting·OOrbus Therapeutics, Inc.·Phase 1·NCT05879367·66 enrolled
Page 1 of 41

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)